We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Disc Medicine Inc | NASDAQ:IRON | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.22 | 4.02% | 31.58 | 31.51 | 31.65 | 32.18 | 30.79 | 30.81 | 49,751 | 16:38:05 |
From May 2023 to May 2024
By Denny Jacob
Disc Medicine's MWTX-003, a treatment for patients with polycythemia vera, was granted fast track designation by the U.S. Food and Drug Administration.
Chief Executive John Quisel said the clinical-stage biopharmaceutical company plans to initiate a Phase 1 trial in the coming months.
MWTX-003 is an investigational monoclonal antibody designed to increase hepcidin production and suppress serum iron.
Polycythemia vera is a chronic and rare myeloproliferative neoplasm characterized by the abnormal proliferation of red blood cells.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
September 20, 2023 17:03 ET (21:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Disc Medicine Chart |
1 Month Disc Medicine Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
